S.No Trial no Title Phase
1 NCT00428519 Effects of treatment with aprepitant (Emend_) in HIV-infected individuals I
2 NCT00835965 Oral aprepitant and lower dose dexamethasone versus aprepitant alone for preventing postoperative nausea and vomiting (PONV) after elective laparoscopic surgeries IV
3 NCT00738621 Combination antiemetic regimen for prevention of PONV in breast surgery IV
4 NCT00717054 Comparison of oral aprepitant alone versus oral aprepitant and transdermal scopolamine for preventing postoperative nausea and vomiting III
5 NCT00572572 Aprepitant + 5HT3 + dexamethasone in patients with germ cell tumours (there is significant increase in CR rate) IV
6 NCT00659737 A randomized, double-blind comparison of oral aprepitant alone versus oral aprepitant and transdermal scopolamine for preventing postoperative nausea and vomiting II
7 NCT00869310 Aprepitant in the prevention of cisplatin-induced delayed emesis IV
8 NCT00651755 Aprepitant effect on drug metabolism in multi-day combination (CHOP/R-CHOP) chemotherapy regimen in lymphoma patients IV
9 NCT00659945 Effectiveness of aprepitant in the treatment of postoperative nausea and vomiting (PONV) in patients undergoing outpatient plastic surgery III
10 NCT01534637 Aprepitant in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer III
11 NCT00415103 Aprepitant plus palonosetron versus granisetron in the prevention of nausea and the emesis induced by chemotherapy in patients treated with hematopoietic progenitors II
12 NCT00734929 Aprepitant with dexamethasone versus ondansetron with dexamethasone for postoperative nausea and vomiting (PONV) prophylaxis in patients having craniotomy II
13 NCT00869973 Aprepitant in the prevention of delayed emesis induced by cyclophosphamide plus anthracyclines in breast cancer Condition: nausea, vomiting II
14 NCT00619359 Emesis Prevention of chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin chemotherapy noninferior II
15 NCT00719173 Effect of aprepitant on cyclophosphamide pharmacokinetics in patients with breast cancer II
16 NCT00736073 A trial of aprepitant for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis II
17 NCT00631930 Palonosetron, aprepitant, and low-dose dexamethasone in preventing nausea and vomiting in patients undergoing high-dose chemotherapy and stem cell transplant for multiple myeloma or lymphoma II
18 NCT00895245 Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation II
19 NCT00293384 Aprepitant, granisetron, and dexamethasone in preventing nausea and vomiting in patients receiving cyclophosphamide before a stem cell transplant II
20
NCT00314743
Oral neurokinin-1 antagonist, aprepitant, in combination with ondansetron and dexamethasone in patients undergoing autologous peripheral blood stem cell transplantation
IV
21
NCT00588835
Pharmacokinetic study on the addition of aprepitant to cisplatin–etoposide treatment in lung cancer patients
III
22 NCT00571168 Efficacy and safety of aprepitant in subjects with multiple myeloma during and after high-dose chemotherapy III
23 NCT00475085 Granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron in preventing nausea in women undergoing chemotherapy for breast cancer III
24
NCT00888329
Aprepitant for prevention of postoperative nausea and vomiting in elective hysterectomy Condition: postoperative nausea and vomiting
I
25 NCT00819039 A study of aprepitant (MK0869) in paediatric patients undergoing surgery condition: postoperative nausea and vomiting I
26
NCT00818259
Recruiting a study of aprepitant (MK0869) and fosaprepitant (MK0517) in paediatric patients receiving chemotherapy Condition: chemotherapy-induced nausea and vomiting
II
27
NCT00896038
The effect of NK1R antagonism on alcohol craving and PTSD symptoms in alcohol dependent patients with PTSD Conditions: alcoholism; alcohol dependence; post-traumatic stress disorder; FMRI
II